{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Complete Response/ near Complete Response"},{"measurements":[{"groupId":"OG000","value":"13"}],"title":"Very Good Partial Response"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Minimal Response"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Unevaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"To evaluate the response rate for weekly administered bortezomib + dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for transplant or who are eligible but wish to postpone autologous stem cell transplant.","groups":[{"description":"Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.\n\nBortezomib: Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.\n\nDexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.","id":"OG000","title":"Bortezomib and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Data was collected for each subject for the duration of the participation in the study, which was an average of 4.8 cycles.","title":"Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete Resonse)","type":"PRIMARY","unitOfMeasure":"Participants"}